Video: Alacrita's Walker On What's Wrong With Risk-Adjusted Net Present Values
This article was originally published in Scrip
Anthony Walker, managing partner of life sciences consulting firm Alacrita, chats to Mike Ward, global director of content for Informa Pharma Insights, at BIO-Europe in Munich, Germany, about what's wrong with risk-adjusted net present values. They cover the problem with this tool, other methods of probability assessment, and how companies should be negotiating prices.
Register for our free email digests: